Dr. John Bartlett

Program Director, Diagnostic Development

Personalized medicine requires personalized diagnostics. As the impact of the deep molecular characterization of cancer and other diseases is translated into clinical management of patients a new wave of molecular diagnostic tools are emerging. Dr. John Bartlett’s research is focused on the development of novel diagnostic approaches to stratified medicine predominantly in breast and prostate cancer. By deep molecular analysis across large clinical cohorts, linked to mechanistic understanding of pathways driving therapeutic resistance, he is developing and validating novel approaches to molecular diagnostics in cancer. These novel approaches will increasingly enable a personalized or stratified treatment approach, in the clinical setting, for cancer patients across Ontario and beyond.

Current affiliations

  • Program Director, Diagnostic Development, OICR;
  • Honorary Professor, College of Medicine and Veterinary Medicine, University of Edinburgh;
  • Provincial Principal Investigator, Ontario Tumour Bank;
  • Affiliate Scientist, University Health Network, Toronto;
  • Honorary Professor, School of Molecular and Clinical Medicine, College of Medicine and Veterinary Medicine, The University of Edinburgh;
  • Professor (Status-Only), Department of Laboratory Medicine and Pathobiology, University of Toronto.

Research interests

  • Breast cancer;
  • Prostate cancer;
  • Molecular diagnostics;
  • Molecular pathology;
  • Clinical trials;
  • Targeted therapeutics.

Select publications

Bayani J, Yao CQ, Auintayo MA, Yan F, Haider S, D’Costa A, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Boutros PC, Bartlett JMS.
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Nature Breast Cancer (accepted Sep 2016)

ICGCmed Scientific Planning Committee and co-author of the ICGCmed White Paper: Zeps N, Awadalla P, Bartlett JMS, Dancey J, Hudson T, Jennings J, Joly Y, Knoppers B, Ouellette F, Stein L, et all.
The Case of the International Cancer Genome Consortium for Medicine. International Cancer Genome Consortium for Medicine

Bartlett JMS, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O’Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen M-B, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI; for the HER2/TIIα meta-analysis study group.
Predicting Anthracycline Benefit: TOP2A and CEP17–Not Only but Also.
JCO May 2015;33(15):1680-7

Bartlett JMS, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, MacPherson IR, Canney P, Francis A, McCabe C, Pinder CE, Hughes-Davies L, Makris A, Stein RC, on behalf of the OPTIMA TMG.
Comparing breast cancer multi-parameter tests in the OPTIMA prelim trial: No test is more equal than the others.
JNCI Natl Cancer Inst. April 2016; 108(9): djw050

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF.
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update.
Journal of Clinical Oncology November 2013;31(31):3997-4013

Previous experience and education

  • Reader, University Department of Surgery, Level II Queen Elizabeth Building, Glasgow Royal Infirmary, University of Glasgow;
  • Reader in Molecular Pathology, School of Molecular and Clinical Medicine, College of Medicine and Veterinary Medicine, The University of Edinburgh;
  • Professor of Molecular Pathology, School of Molecular and Clinical Medicine, College of Medicine and Veterinary Medicine, The University of Edinburgh.

Opportunities to collaborate

Collaboration is the key to solving the big questions faced by researchers across the cancer spectrum. In Bartlett’s program there are opportunities to collaborate through technology access, partnership and mentorship. Bartlett’s expertise in diagnostic development and both in situ and deep molecular analysis of clinical specimens provides an ideal platform for partnership with researchers across Ontario, Canada and beyond. Bartlett is always willing to discuss scientific opportunities and solutions (over a coffee!) and to foster a collaborative approach with research and industry partners. For more opportunities visit OICR’s Collaborative Research Resources page.


William To
Program Manager